Alternatively spliced androgen receptor variants

被引:292
作者
Dehm, Scott M. [1 ]
Tindall, Donald J. [2 ]
机构
[1] Univ Minnesota, Dept Lab Med & Pathol, Masonic Canc Ctr, Minneapolis, MN 55455 USA
[2] Mayo Clin, Dept Urol Res, Rochester, MN USA
关键词
RESISTANT PROSTATE-CANCER; AMINO-TERMINAL DOMAIN; STRUCTURAL BASIS; BINDING DOMAIN; ANTITUMOR-ACTIVITY; POINT MUTATION; GENE-MUTATIONS; MESSENGER-RNA; SITE MUTATION; DONOR SITE;
D O I
10.1530/ERC-11-0141
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Alternative splicing is an important mechanism for increasing functional diversity from a limited set of genes. Deregulation of this process is common in diverse pathologic conditions. The androgen receptor (AR) is a steroid receptor transcription factor with functions critical for normal male development as well as the growth and survival of normal and cancerous prostate tissue. Studies of AR function in androgen insensitivity syndrome (AIS) and prostate cancer (PCa) have demonstrated loss-of-function AR alterations in AIS and gain-of-function AR alterations in PCa. Over the past two decades, AR gene alterations have been identified in various individuals with AIS, which disrupt normal AR splicing patterns and yield dysfunctional AR protein variants. Recently, altered AR splicing patterns have been identified as a mechanism of PCa progression and resistance to androgen depletion therapy. Several studies have described the synthesis of alternatively spliced transcripts encoding truncated AR isoforms that lack the ligand-binding domain, which is the ultimate target of androgen depletion. Many of these truncated AR isoforms function as constitutively active, ligand-independent transcription factors that can support androgen-independent expression of AR target genes, as well as the androgen-independent growth of PCa cells. In this review, we will summarize the various alternatively spliced AR variants that have been discovered, with a focus on their role and origin in the pathologic conditions of AIS and PCa. Endocrine-Related Cancer (2011) 18 R183-R196
引用
收藏
页码:R183 / R196
页数:14
相关论文
共 57 条
[1]   Androgen receptor action in hormone-dependent and recurrent prostate cancer [J].
Agoulnik, Irina U. ;
Weigel, Nancy L. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 99 (02) :362-372
[2]   Androgen receptor function is modulated by the tissue-specific AR45 variant [J].
Ahrens-Fath, I ;
Politz, O ;
Geserick, C ;
Haendler, B .
FEBS JOURNAL, 2005, 272 (01) :74-84
[3]  
Alen P, 1999, MOL CELL BIOL, V19, P6085
[4]   Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven [J].
Attard, Gerhardt ;
Reid, Alison H. M. ;
Olmos, David ;
de Bono, Johann S. .
CANCER RESEARCH, 2009, 69 (12) :4937-4940
[5]   Nuclear receptor structure: Implications for function [J].
Bain, David L. ;
Heneghan, Aaron F. ;
Connaghan-Jones, Keith D. ;
Miura, Michael T. .
ANNUAL REVIEW OF PHYSIOLOGY, 2007, 69 :201-220
[6]   Molecular basis of androgen insensitivity [J].
Brinkmann, AO .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2001, 179 (1-2) :105-109
[7]   Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: An unusual type of intronic mutation [J].
Bruggenwirth, HT ;
Boehmer, ALM ;
Ramnarain, S ;
VerleunMooijman, MCT ;
Satijn, DPE ;
Trapman, J ;
Grootegoed, JA ;
Brinkmann, AO .
AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (05) :1067-1077
[8]   Interplay between two hormone-independent activation domains in the androgen receptor [J].
Callewaert, L ;
Van Tilborgh, N ;
Claessens, F .
CANCER RESEARCH, 2006, 66 (01) :543-553
[9]   Delineation of two distinct type I activation functions in the androgen receptor amino-terminal domain [J].
Chamberlain, NL ;
Whitacre, DC ;
Miesfeld, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (43) :26772-26778
[10]   ERK Regulates Calpain 2-induced Androgen Receptor Proteolysis in CWR22 Relapsed Prostate Tumor Cell Lines [J].
Chen, Honglin ;
Libertini, Stephen J. ;
Wang, Yu ;
Kung, Hsing-Jien ;
Ghosh, Paramita ;
Mudryj, Maria .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (04) :2368-2374